{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T04:35:14Z","timestamp":1777091714577,"version":"3.51.4"},"reference-count":24,"publisher":"Pharmaceutical Society of Japan","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,4,21]]},"DOI":"10.1248\/bpb.b25-00814","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:11:10Z","timestamp":1776723070000},"page":"743-752","source":"Crossref","is-referenced-by-count":0,"title":["Establishment of a Rat Model for Renal Anemia Based on 5\/6 Nephrectomized Rats"],"prefix":"10.1248","volume":"49","author":[{"given":"Yuko","family":"Nakayama","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Himeji, Hy\u014dgo 670\u20138524, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Kamikawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Himeji, Hy\u014dgo 670\u20138524, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satohiro","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Himeji, Hy\u014dgo 670\u20138524, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Gunawardena S, Dayaratne M, Wijesinghe H, Wijewickrama E. A Systematic review of renal pathology in chronic kidney disease of uncertain etiology. <i>Kidney Int. Rep.<\/i>, <b>6<\/b>, 1711\u20131728 (2021).","DOI":"10.1016\/j.ekir.2021.03.898"},{"key":"2","unstructured":"2) National Kidney Foundation. K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. <i>Am. J. Kidney Dis.<\/i>, <b>39<\/b> (Suppl. 1), S1\u2013S266 (2002)."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. <i>J. Clin. Invest.<\/i>, <b>76<\/b>, 612\u2013619 (1985).","DOI":"10.1172\/JCI112013"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Ji L, Masuda S, Saito H, Inui K. Down-regulation of rat organic cation transporter rOCT2 by 5\/6 nephrectomy. <i>Kidney Int.<\/i>, <b>62<\/b>, 514\u2013524 (2002).","DOI":"10.1046\/j.1523-1755.2002.00464.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Souma T, Suzuki N, Yamamoto M. Renal erythropoietin-producing cells in health and disease. <i>Front. Physiol.<\/i>, <b>6<\/b>, 167 (2015).","DOI":"10.3389\/fphys.2015.00167"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Matsuoka T, Abe M, Kobayashi H. Iron metabolism and inflammatory mediators in patients with renal dysfunction. <i>Int. J. Mol. Sci.<\/i>, <b>25<\/b>, 3745 (2024).","DOI":"10.3390\/ijms25073745"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Brunet M, van Gelder T, Asberg A, <i>et al<\/i>. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. <i>Ther. Drug Monit.<\/i>, <b>41<\/b>, 261\u2013307 (2019).","DOI":"10.1097\/FTD.0000000000000640"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Maslauskiene R, Vaiciuniene R, Radzeviciene A, Tretjakovs P, Gersone G, Stankevicius E, Bumblyte IA. The influence of tacrolimus exposure and metabolism on the outcomes of kidney transplants. <i>Biomedicines<\/i>, <b>12<\/b>, 1125 (2024).","DOI":"10.3390\/biomedicines12051125"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Fu R, Tajima S, Shigematsu T, Zhang M, Tsuchimoto A, Egashira N, Ieiri I, Masuda S. Establishment of an experimental rat model of tacrolimus-induced kidney injury accompanied by interstitial fibrosis. <i>Toxicol. Lett.<\/i>, <b>341<\/b>, 43\u201350 (2021).","DOI":"10.1016\/j.toxlet.2021.01.020"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Horiba N, Masuda S, Takeuchi A, Saito H, Okuda M, Inui K. Gene expression variance based on random sequencing in rat remnant kidney. <i>Kidney Int.<\/i>, <b>66<\/b>, 29\u201345 (2004).","DOI":"10.1111\/j.1523-1755.2004.00704.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Nishihara K, Masuda S, Ji L, Katsura T, Inui K. Pharmacokinetic significance of luminal multidrug and toxin extrusion 1 in chronic renal failure rats. <i>Biochem. Pharmacol.<\/i>, <b>73<\/b>, 1482\u20131490 (2007).","DOI":"10.1016\/j.bcp.2006.12.034"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Shimizu Y, Masuda S, Nishihara K, Ji L, Okuda M, Inui K. Increased protein level of PEPT1 intestinal H<sup>+<\/sup>-peptide cotransporter upregulates absorption of glycylsarcosine and ceftibuten in 5\/6 nephrectomized rats. <i>Am. J. Physiol. Gastrointest. Liver Physiol.<\/i>, <b>288<\/b>, G664\u2013G670 (2005).","DOI":"10.1152\/ajpgi.00270.2004"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. <i>Anal. Biochem.<\/i>, <b>72<\/b>, 248\u2013254 (1976).","DOI":"10.1016\/0003-2697(76)90527-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Heckl SM, Wiesener V, Behrens HM, Ulase D, Kr\u00fcger S, R\u00f6cken C. The expression of the insulin receptor in gastric cancer correlates with the HER2 status and may have putative therapeutic implications. <i>Gastric Cancer<\/i>, <b>22<\/b>, 1130\u20131142 (2019).","DOI":"10.1007\/s10120-019-00964-6"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Koury MJ, Haase VH. Anaemia in kidney disease: harnessing hypoxia responses for therapy. <i>Nat. Rev. Nephrol.<\/i>, <b>11<\/b>, 394\u2013410 (2015).","DOI":"10.1038\/nrneph.2015.82"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: A paradigm shift in nephrology. <i>Kidney Int.<\/i>, <b>49<\/b>, 1774\u20131777 (1996).","DOI":"10.1038\/ki.1996.265"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Landau D, London L, Bandach I, Segev Y. The hypoxia inducible factor\/erythropoietin (EPO)\/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia. <i>PLOS ONE<\/i>, <b>13<\/b>, e0196684 (2018).","DOI":"10.1371\/journal.pone.0196684"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Awan AA, Walther CP, Richardson PA, Shah M, Winkelmayer WC, Navaneethan SD. Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease. <i>Nephrol. Dial. Transplant.<\/i>, <b>36<\/b>, 129\u2013136 (2021).","DOI":"10.1093\/ndt\/gfz192"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Mercadal L, Metzger M, Haymann JP, Thervet E, Boffa JJ, Flamant M, Vrtovsnik F, Houillier P, Froissart M, Stengel B. The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. <i>PLOS ONE<\/i>, <b>9<\/b>, e99781 (2014).","DOI":"10.1371\/journal.pone.0099781"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. <i>Clin. J. Am. Soc. Nephrol.<\/i>, <b>4<\/b>, 481\u2013508 (2009).","DOI":"10.2215\/CJN.04800908"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Tamada S, Nakatani T, Asai T, Tashiro K, Komiya T, Sumi T, Okamura M, Kim S, Iwao H, Kishimoto T, Yamanaka S, Miura K. Inhibition of nuclear factor-\u03baB activation by pyrrolidine dithiocarbamate prevents chronic FK506 nephropathy. <i>Kidney Int.<\/i>, <b>63<\/b>, 306\u2013314 (2003).","DOI":"10.1046\/j.1523-1755.2003.00714.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Nady ME, Abd El-Raouf OM, El-Sayed EM. Linagliptin mitigates TGF-\u03b21 mediated epithelial-mesenchymal transition in tacrolimus-induced renal interstitial fibrosis <i>via<\/i> Smad\/ERK\/P38 and HIF-1\u03b1\/LOXL2 signaling pathways. <i>Biol. Pharm. Bull.<\/i>, <b>47<\/b>, 1008\u20131020 (2024).","DOI":"10.1248\/bpb.b23-00737"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Badura K, Janc J, W\u0105sik J, Gnitecki S, Skwira S, M\u0142ynarska E, Rysz J, Franczyk B. Anemia of chronic kidney disease\u2014a narrative review of its pathophysiology, diagnosis, and management. <i>Biomedicines<\/i>, <b>12<\/b>, 1191 (2024).","DOI":"10.3390\/biomedicines12061191"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) de Oliveira J\u00fanior WV, Sabino Ade P, Figueiredo RC, Rios DR. Inflammation and poor response to treatment with erythropoietin in chronic kidney disease. <i>J. Bras. Nefrol.<\/i>, <b>37<\/b>, 255\u2013263 (2015).","DOI":"10.5935\/0101-2800.20150039"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/4\/49_b25-00814\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T03:39:17Z","timestamp":1777088357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/4\/49_b25-00814\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00814","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"article-number":"b25-00814"}}